Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Cash from Financing Activities (2016 - 2025)

Immucell's Cash from Financing Activities history spans 16 years, with the latest figure at -$394602.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 365.07% year-over-year to -$394602.0; the TTM value through Dec 2025 reached -$1.2 million, down 142.06%, while the annual FY2025 figure was -$1.2 million, 142.06% down from the prior year.
  • Cash from Financing Activities reached -$394602.0 in Q4 2025 per ICCC's latest filing, down from -$337689.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $4.0 million in Q2 2021 to a low of -$403647.0 in Q1 2025.
  • Average Cash from Financing Activities over 5 years is $420742.0, with a median of -$185665.0 recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: plummeted 528.91% in 2021, then surged 1114.39% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at -$194905.0 in 2021, then fell by 27.35% to -$248209.0 in 2022, then dropped by 29.5% to -$321433.0 in 2023, then skyrocketed by 146.31% to $148866.0 in 2024, then plummeted by 365.07% to -$394602.0 in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Cash from Financing Activities are -$394602.0 (Q4 2025), -$337689.0 (Q3 2025), and -$76448.0 (Q2 2025).